Tata Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to provide income distribution and / or medium to long term capital gains. Investment would be focussed towards mid cap stocks.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 71% of rolling 3-year windows.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.84% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -35.1%. Ask whether you can hold through a similar fall.
Vs category
Pass
71% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Satish Chandra Mishra · 5.6 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 29.8% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 35%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
7 Feb 2020 – 5 Nov 2020
Trough 23 Mar 2020 · recovered in 227 days
-35.1%
8 Jan 2018 – 24 Jan 2020
Trough 9 Oct 2018 · recovered in 472 days
-24.8%
5 Aug 2015 – 9 Aug 2016
Trough 29 Feb 2016 · recovered in 162 days
-22.3%
27 Sept 2024 – 2 Jan 2026
Trough 28 Feb 2025 · recovered in 308 days
-21.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
41
Vs category
47
Consistency
64
Risk-adjusted
64
Drawdown
12
Mean
46
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 60 holdings · top 10 are 29.8%.
Mankind Pharma Ltd.
Healthcare
3.4%
Bharat Heavy Electricals Ltd
Industrials
3.2%
One 97 Communications Ltd
Industrials
3.1%
Multi Commodity Exchange Of India Ltd
Financial
3.0%
L&T Finance Holdings Ltd
Financial
2.9%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Baroda BNP Paribas Mutual Fund
Union Mutual Fund
Caveat: Higher TER
HDFC Mutual Fund
Caveat: Deeper drawdown
Axis Mutual Fund
ITI Mutual Fund
Caveat: Higher volatility · Higher TER
Tata Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to provide income distribution and / or medium to long term capital gains. Investment would be focussed towards mid cap stocks.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 71% of rolling 3-year windows.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.84% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -35.1%. Ask whether you can hold through a similar fall.
Vs category
Pass
71% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Satish Chandra Mishra · 5.6 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 29.8% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 35%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
30 Oct 2026 · -2.7% over 1Y
492.5189
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
30 Oct 2026
-9.6%
7 Feb 2020 – 5 Nov 2020
Trough 23 Mar 2020 · recovered in 227 days
-35.1%
8 Jan 2018 – 24 Jan 2020
Trough 9 Oct 2018 · recovered in 472 days
-24.8%
5 Aug 2015 – 9 Aug 2016
Trough 29 Feb 2016 · recovered in 162 days
-22.3%
27 Sept 2024 – 2 Jan 2026
Trough 28 Feb 2025 · recovered in 308 days
-21.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
41
Vs category
47
Consistency
64
Risk-adjusted
64
Drawdown
12
Mean
46
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 60 holdings · top 10 are 29.8%.
Mankind Pharma Ltd.
Healthcare
3.4%
Bharat Heavy Electricals Ltd
Industrials
3.2%
One 97 Communications Ltd
Industrials
3.1%
Multi Commodity Exchange Of India Ltd
Financial
3.0%
L&T Finance Holdings Ltd
Financial
2.9%